Legal & General Group Plc - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.

Quarter-by-quarter ownership
Legal & General Group Plc ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$3,047,939
-15.7%
67,150
+4.2%
0.00%0.0%
Q2 2023$3,617,382
+30.9%
64,435
+5.5%
0.00%0.0%
Q1 2023$2,763,282
+23.5%
61,094
+11.0%
0.00%0.0%
Q4 2022$2,237,985
-37.1%
55,055
+1.1%
0.00%0.0%
Q3 2022$3,557,000
+5.8%
54,436
-1.6%
0.00%0.0%
Q2 2022$3,361,000
+1.7%
55,306
+5.0%
0.00%0.0%
Q1 2022$3,306,000
-16.1%
52,677
+1.3%
0.00%0.0%
Q4 2021$3,940,000
-26.2%
52,002
+9.0%
0.00%
-50.0%
Q3 2021$5,338,000
-7.8%
47,691
+33.3%
0.00%0.0%
Q2 2021$5,790,000
+43.0%
35,765
+7.6%
0.00%0.0%
Q1 2021$4,050,000
-10.0%
33,235
+13.1%
0.00%0.0%
Q4 2020$4,499,000
+75.7%
29,381
-4.0%
0.00%
+100.0%
Q3 2020$2,560,000
+32.1%
30,599
+16.0%
0.00%0.0%
Q2 2020$1,938,000
+352.8%
26,378
+190.6%
0.00%
Q1 2020$428,000
-79.2%
9,077
-73.2%
0.00%
-100.0%
Q4 2019$2,060,000
+4581.8%
33,830
+3018.0%
0.00%
Q3 2019$44,000
-13.7%
1,0850.0%0.00%
Q2 2019$51,000
+168.4%
1,085
+100.9%
0.00%
Q1 2019$19,000
+26.7%
5400.0%0.00%
Q4 2018$15,000
+87.5%
540
+182.7%
0.00%
Q3 2018$8,000
-27.3%
1910.0%0.00%
Q2 2018$11,0001910.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2023
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$27,989,04633.20%
Gilfoyle Management LLC 100$4,84215.90%
NEA Management Company, LLC 1,587,854$89,142,1246.80%
ARK Investment Management 7,338,447$411,980,3942.73%
Nikko Asset Management Americas, Inc. 3,533,357$198,327,3282.09%
Del-Sette Capital Management, LLC 33,661$1,889,7291.79%
Ikarian Capital, LLC 200,000$11,228,0001.79%
Ikarian Capital, LLC 200,000$11,228,0001.79%
Merlin Capital, Inc 8,802$494,1441.67%
Green Alpha Advisors, LLC 34,373$1,929,7001.27%
View complete list of CRISPR THERAPEUTICS AG shareholders